MA39100A1 - Compositions and methods for reducing major adverse cardiovascular events - Google Patents
Compositions and methods for reducing major adverse cardiovascular eventsInfo
- Publication number
- MA39100A1 MA39100A1 MA39100A MA39100A MA39100A1 MA 39100 A1 MA39100 A1 MA 39100A1 MA 39100 A MA39100 A MA 39100A MA 39100 A MA39100 A MA 39100A MA 39100 A1 MA39100 A1 MA 39100A1
- Authority
- MA
- Morocco
- Prior art keywords
- adverse cardiovascular
- methods
- compositions
- mace
- cardiovascular events
- Prior art date
Links
Abstract
La présente invention concerne des compositions, des kits, des utilisations, des systèmes et des procédés pour utiliser de la naltrexone et du bupropion, ou des sels pharmaceutiquement acceptables de ces derniers, pour réduire le risque de conséquences ou d'événements cardiovasculaires indésirables, y compris des événements cardiovasculaires indésirables majeurs (mace) chez des sujets, de préférence ceux ayant un risque accru de conséquences cardiovasculaires indésirables ou mace, qui peuvent être en surpoids ou obèses. La présente invention concerne également des compositions, des kits, des utilisations, des systèmes et des procédés pour utiliser de la naltrexone et du bupropion, ou des sels pharmaceutiquement acceptables de ces derniers, pour le traitement du surpoids ou de l'obésité chez des sujets, de préférence ayant un risque accru de conséquences cardiovasculaires indésirables ou mace, le traitement réduisant le risque de mace.The present invention provides compositions, kits, uses, systems and methods for using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, to reduce the risk of adverse cardiovascular events or events, including including major adverse cardiovascular events (mace) in subjects, preferably those with an increased risk of adverse cardiovascular consequences or mace, who may be overweight or obese. The present invention also relates to compositions, kits, uses, systems and methods for using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for the treatment of overweight or obesity in subjects , preferably having an increased risk of adverse cardiovascular consequences or mace, the treatment reducing the risk of mace.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 | |
| US201361914935P | 2013-12-11 | 2013-12-11 | |
| US201461984580P | 2014-04-25 | 2014-04-25 | |
| US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
| PCT/US2014/068527 WO2015085044A1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39100A1 true MA39100A1 (en) | 2018-01-31 |
| MA39100B1 MA39100B1 (en) | 2019-12-31 |
Family
ID=61759232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39100A MA39100B1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA39100B1 (en) |
-
2014
- 2014-12-04 MA MA39100A patent/MA39100B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA39100B1 (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690964A1 (en) | COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR PHENOMENA | |
| WO2010094009A3 (en) | Methods and compositions for the treatment of ras associated disorders | |
| EA201291309A1 (en) | USING SGC STIMULATORS, SGC ACTIVATORS, ONE AND IN COMBINATION WITH PDE5 INHIBITORS, TO TREAT SYSTEMIC SCLEROSIS | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| EA201200793A1 (en) | TREATMENT OF GENOTYPED PATIENTS WITH DIABETES DPP-4 INHIBITORS, SUCH AS LINAGLIPTIN | |
| MA39211A1 (en) | Tricyclic compounds as anti-cancer agents | |
| MA34002B1 (en) | ANTIVIRAL THERAPY | |
| EA201291031A1 (en) | METHOD OF TREATING OBESITY WITH THE USE OF ANTIOXIDANT INFLAMMATION MODULATORS | |
| UA109650C2 (en) | BIS-ARLYZED ARILTRIAZOLONS AND THEIR APPLICATIONS | |
| MX349787B (en) | Oral dosage forms including an antiplatelet agent and an acid inhibitor. | |
| MA37714A1 (en) | Methods of treating overweight and obesity | |
| EA201270567A1 (en) | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
| RS53467B (en) | Use of amisulpride for treating chemotherapy-induced nausea and vomiting | |
| WO2011035205A3 (en) | Antibodies against candida, collections thereof and methods of use | |
| BR112012029919A2 (en) | process for the preparation of 5-substituted 8-alkoxy [1,2,4] triazolo [1,5-c] pyrimidin-2-amines | |
| EA201591379A1 (en) | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA) INHIBITORS BASED ON 2,3-DIHYDROIMIDAZO [1,2-С] PYRIMIDIN-5 (1H) -OH | |
| ATE548050T1 (en) | DIAGNOSTIC PROCEDURE | |
| CA3010708A1 (en) | Methods of administering hepcidin | |
| MA33839B1 (en) | Combinations and methods of diagnosis and treatment of tumors | |
| MX2017009929A (en) | Compositions and methods for improved muscle metabolism. | |
| EA201500913A1 (en) | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
| WO2015126930A3 (en) | Booster drug therapy for mycobacterium infections | |
| MX2009004142A (en) | Method of preventing or treating metabolic syndrome. | |
| MA39100A1 (en) | Compositions and methods for reducing major adverse cardiovascular events | |
| EP3449917A3 (en) | Tapentadol for preventing chronification of pain |